Smith & Nephew PLC
LSE:SN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
917.6
1 208.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Smith & Nephew PLC
Intrinsic Value
The intrinsic value of one
SN
stock under the Base Case scenario is
1 458.57
GBX.
Compared to the current market price of 986.8 GBX,
Smith & Nephew PLC
is
Undervalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Smith & Nephew PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Smith & Nephew PLC has a rich history dating back to 1856, evolving from a small medical supplies company in the UK to a prominent global player in the medical technology industry. The company specializes in advanced wound management, surgical devices, and orthopedic reconstruction, driven by a mission to restore people’s bodies and health, enabling them to live life to the fullest. As an investor, you’ll find that Smith & Nephew stands out for its commitment to innovation, consistently investing a significant portion of its revenue into research and development. This dedication results in a robust pipeline of cutting-edge products, such as its highly regarded advanced wound care solutions a...
Smith & Nephew PLC has a rich history dating back to 1856, evolving from a small medical supplies company in the UK to a prominent global player in the medical technology industry. The company specializes in advanced wound management, surgical devices, and orthopedic reconstruction, driven by a mission to restore people’s bodies and health, enabling them to live life to the fullest. As an investor, you’ll find that Smith & Nephew stands out for its commitment to innovation, consistently investing a significant portion of its revenue into research and development. This dedication results in a robust pipeline of cutting-edge products, such as its highly regarded advanced wound care solutions and knee and hip reconstruction devices. The company’s strategic focus on emerging markets and partnerships with healthcare providers positions it well for sustainable growth amid shifts in the global healthcare landscape.
Navigating the complexities of the healthcare sector, Smith & Nephew demonstrates resilience through its diversified product range and broad geographic presence, generating revenue from both developed and developing markets. The company has been enhancing its operational efficiency, improved profit margins, and reduced costs, which resonate well with value investors seeking financially sound opportunities. Furthermore, the company’s commitment to environmental, social, and governance (ESG) principles may appeal to socially conscious investors. As Smith & Nephew continues to leverage technological advancements and respond to the evolving needs of healthcare systems, its story remains compelling – offering not just potential financial returns but also a commitment to improving patient outcomes and enhancing the quality of life around the globe.
Smith & Nephew PLC is a global medical technology company specializing in advanced wound management, orthopedics, sports medicine, and trauma surgery. Here are the core business segments of Smith & Nephew:
-
Advanced Wound Management:
- This segment focuses on products and technologies for the treatment of wounds, including chronic and complex wounds. It includes various advanced dressings, negative pressure wound therapy, and bioactive products intended to enhance healing and improve patient outcomes.
-
Orthopedics:
- This segment includes joint replacement and reconstruction products, which are designed to address conditions related to osteoarthritis and other joint-related issues. Smith & Nephew offers a range of implants and surgical instruments for hip, knee, and upper extremities, emphasizing minimally invasive surgical techniques and innovative materials.
-
Sports Medicine & Shoulder:
- Smith & Nephew provides a wide array of products used in minimally invasive surgery to treat sports-related injuries and conditions. This segment features a range of arthroscopic instruments, fixation devices, and biologics aimed at repairing soft tissue injuries, with a particular focus on shoulder surgeries.
-
Trauma & Extremities:
- This segment encompasses products and solutions for trauma surgery and extremity procedures. It includes plates, screws, and fixation devices used in surgical interventions for fractures, particularly in the long bones and the foot and ankle.
Each of these segments reflects the company’s focus on innovation, quality, and improving patient care through advanced medical technologies. Overall, Smith & Nephew aims to enhance clinical outcomes and patient experiences across various medical specialties.
Smith & Nephew PLC, a global medical technology company specializing in orthopedic reconstruction, advanced wound management, and sports medicine, possesses several competitive advantages that set it apart from its rivals:
-
Innovative Product Portfolio: Smith & Nephew is known for its strong emphasis on innovation. The company invests significantly in research and development, leading to the introduction of cutting-edge products. This focus on innovation helps maintain a strong product pipeline and attracts healthcare providers looking for the latest medical solutions.
-
Robust Intellectual Property: The company has a substantial portfolio of patents and proprietary technologies, which can provide protection against competitors and enhance its product offerings. Strong IP can also be a significant barrier to entry for new competitors in the medical technology field.
-
Global Presence with Local Expertise: Smith & Nephew operates in over 100 countries, giving it a wide geographic reach. This global footprint, combined with local market knowledge, allows the company to tailor its products and marketing strategies to meet specific regional needs and regulatory requirements.
-
Strong Brand Recognition: Smith & Nephew has established a solid brand reputation in the medical field, particularly for its orthopedic and wound care products. This brand strength can translate into customer loyalty and preference, giving it an edge over competitors.
-
Comprehensive Training and Support: The company offers extensive training and support to healthcare providers using its products. This commitment to education enhances the effectiveness of medical professionals and encourages loyalty to Smith & Nephew’s products.
-
Strategic Partnerships and Collaborations: Smith & Nephew has established partnerships with various healthcare organizations, academic institutions, and technology companies. These collaborations can drive innovation, improve product offerings, and expand market access.
-
Focus on Emerging Markets: The company's strategy includes a focus on growth in emerging markets where demand for healthcare solutions is increasing. This positions Smith & Nephew to capture new revenue streams as healthcare systems in these regions mature.
-
Diverse Revenue Streams: With a diverse range of products across different healthcare segments (orthopedics, wound care, and sports medicine), the company is less vulnerable to market fluctuations in any single area.
-
Customer-Centric Approach: Smith & Nephew's commitment to understanding customer needs and delivering high-quality service can enhance customer satisfaction and retention, providing a competitive edge.
-
Sustainability and Corporate Responsibility: Increasingly, companies are judged on their commitment to sustainability and social responsibility. Smith & Nephew has initiatives in place that focus on environmental responsibility and ethical practices, appealing to an evolving consumer base and investor group that values these principles.
These competitive advantages position Smith & Nephew PLC favorably in the medical technology industry, enabling it to navigate challenges and seize growth opportunities effectively.
Smith & Nephew PLC, a global medical technology company, faces several risks and challenges in the near future. Here are some key areas to consider:
-
Regulatory Compliance: The medical device industry is heavily regulated. Changes in regulations or strict compliance requirements can lead to increased costs and delays in product approval.
-
Market Competition: The healthcare sector is highly competitive, with numerous players developing innovative solutions. This competitive pressure can lead to price cuts and reduced market share.
-
Technological Advances: Rapid advancements in medical technology require constant investment in R&D. Failing to keep pace with technological innovations can render existing products obsolete.
-
Supply Chain Disruptions: Global supply chain issues, exacerbated by geopolitical tensions and the COVID-19 pandemic, can impact manufacturing and distribution, leading to delays and increased costs.
-
Economic Factors: Economic downturns can affect healthcare budgets and spending. The company must be prepared for fluctuations in demand for its products in various geographies.
-
Litigation and Liability Risks: Like many medical device companies, Smith & Nephew may face litigation risks related to product efficacy or safety issues. Legal costs and settlements can significantly impact financial performance.
-
Dependence on Key Products: A significant portion of revenue may stem from specific products. A decline in sales of these key items or the loss of patent protection could adversely affect the company.
-
Currency Fluctuations: As an international company, fluctuations in foreign exchange rates can impact revenues and profitability. Currency volatility can be a significant risk if not managed effectively.
-
Talent Acquisition and Retention: As a tech-driven company, attracting and retaining skilled professionals is crucial. Hiring challenges and workforce turnover can affect operational efficiency and innovation.
-
Geopolitical Risks: Operations in multiple countries expose Smith & Nephew to geopolitical instability and trade-related risks, which can disrupt business operations and market access.
Addressing these challenges will require strategic planning, robust risk management processes, and continuous investment in innovation and quality.
Revenue & Expenses Breakdown
Smith & Nephew PLC
Balance Sheet Decomposition
Smith & Nephew PLC
| Current Assets | 4.5B |
| Cash & Short-Term Investments | 568m |
| Receivables | 1.4B |
| Other Current Assets | 2.5B |
| Non-Current Assets | 6.1B |
| Long-Term Investments | 24m |
| PP&E | 1.4B |
| Intangibles | 4.2B |
| Other Non-Current Assets | 403m |
| Current Liabilities | 1.8B |
| Accounts Payable | 1B |
| Short-Term Debt | 328m |
| Other Current Liabilities | 425m |
| Non-Current Liabilities | 3.6B |
| Long-Term Debt | 3.3B |
| Other Non-Current Liabilities | 285m |
Earnings Waterfall
Smith & Nephew PLC
|
Revenue
|
5.6B
USD
|
|
Cost of Revenue
|
-1.7B
USD
|
|
Gross Profit
|
3.9B
USD
|
|
Operating Expenses
|
-3.2B
USD
|
|
Operating Income
|
696m
USD
|
|
Other Expenses
|
-391m
USD
|
|
Net Income
|
305m
USD
|
Free Cash Flow Analysis
Smith & Nephew PLC
| USD | |
| Free Cash Flow | USD |
Smith & Nephew concluded 2023 on a high note, surpassing its already raised revenue growth guidance, with Sports Medicine and ENT experiencing double-digit expansion and Advanced Wound Management sustaining momentum. While Orthopedics improvement is ongoing, their 12-Point Plan fosters advancement, as highlighted by accelerated growth across all business units and a solidified portfolio. The company met its 17.5% target margin, despite inflation and slow market activity in China, and achieved a 7.2% underlying revenue growth, totaling $5.5 billion. Reported growth was slightly lower at 6.4%, due to currency effects. Trading profit saw a 7.6% uptick to $970 million, and a notable $200 million betterment in working capital outflow brought trading cash flow to $635 million. Adjusted earnings per share increased modestly by 1.3% to $0.828. The dividend remained steady at $0.375 for the year. Entering 2024, Smith & Nephew anticipates further growth and margin improvement, even in light of the anticipated headwinds from China's Volume-Based Procurement (VBP).
What is Earnings Call?
SN Profitability Score
Profitability Due Diligence
Smith & Nephew PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
Score
Smith & Nephew PLC's profitability score is 53/100. The higher the profitability score, the more profitable the company is.
SN Solvency Score
Solvency Due Diligence
Smith & Nephew PLC's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Smith & Nephew PLC's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SN Price Targets Summary
Smith & Nephew PLC
According to Wall Street analysts, the average 1-year price target for
SN
is 1 259.7 GBX
with a low forecast of 1 020.1 GBX and a high forecast of 1 543.5 GBX.
Click here to dive deeper.
Dividends
Current shareholder yield for SN is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Smith & Nephew PLC
Country
Industry
Market Cap
Dividend Yield
Description
Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. The company is headquartered in Watford, Hertfordshire and currently employs 18,369 full-time employees. The firm is engaged in designing and manufacturing technology. The company supports healthcare professionals to return their patients to health and mobility by helping them to perform. The company serves its customers through global franchises, which includes Orthopaedics, Sports Medicine and Ear, Nose and Throat (ENT) and Advanced Wound Management. The Orthopaedics includes a range of Hip and Knee Implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that allow surgeons, and Trauma products used to stabilize severe fractures and correct bone deformities. Its Sports Medicine and ENT businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a set of products to meet clinical needs, to help healthcare professionals reduce the human and economic consequences of wounds.
Contact
IPO
Employees
Officers
The intrinsic value of one
SN
stock under the Base Case scenario is
1 458.57
GBX.
Compared to the current market price of 986.8 GBX,
Smith & Nephew PLC
is
Undervalued by 32%.
You don't have any saved screeners yet
